A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.

[1]  S. Steinberg,et al.  Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. , 1994, Cancer research.

[2]  J. Marks,et al.  Overexpression of p53 and HER‐2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer , 1994, Annals of surgery.

[3]  R. Bast,et al.  Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. , 1994, American journal of clinical pathology.

[4]  R. Dodge,et al.  Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. , 1993, Archives of surgery.

[5]  T. Mitsudomi,et al.  Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[6]  J. Iglehart,et al.  Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[7]  A. Harris,et al.  bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.

[8]  C. Angeletti,et al.  Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. , 1993, The Journal of thoracic and cardiovascular surgery.

[9]  T. Muramatsu,et al.  Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas , 1993, Cancer.

[10]  Y. Ichinose,et al.  Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer ? A multivariate prognostic factor analysis of 151 patients. , 1993, The Journal of thoracic and cardiovascular surgery.

[11]  D. Lane,et al.  The relationship of p53 immunostaining to survival in carcinoma of the lung. , 1992, British Journal of Cancer.

[12]  D. Quinlan,et al.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.

[13]  C. Angeletti,et al.  Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.

[14]  J. Marks,et al.  p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[15]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[16]  J. Iglehart,et al.  Proliferation index in various stages of breast cancer determined by ki‐67 immunostaining , 1991, Journal of surgical oncology.

[17]  J. Marks,et al.  Genetic basis for p53 overexpression in human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Sahin,et al.  Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. , 1991, The New England journal of medicine.

[19]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[20]  J. Sørensen,et al.  Prognostic factors in resected stages I and II adenocarcinoma of the lung. A multivariate regression analysis of 137 consecutive patients. , 1990, The Journal of thoracic and cardiovascular surgery.

[21]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[22]  K. Suemasu,et al.  Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 CM in diameter , 1988, Cancer.

[23]  M. Melamed,et al.  Impact of early detection on the clinical course of lung cancer. , 1987, The Surgical clinics of North America.

[24]  S. Piantadosi,et al.  Postoperative T1 N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. The Lung Cancer Study Group. , 1987, The Journal of thoracic and cardiovascular surgery.

[25]  C. Mountain,et al.  A new international staging system for lung cancer. , 1987, Chest.

[26]  M. Gail,et al.  Prognostic factors in patients with resected stage I non‐small cell lung cancer. A report from the Lung Cancer Study Group , 1984, Cancer.

[27]  E. Bergstralh,et al.  Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. , 1984, The Annals of thoracic surgery.

[28]  G W Moore,et al.  Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung , 1984, The American journal of surgical pathology.

[29]  D. Schoenfeld,et al.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. , 1982, Biometrics.

[30]  W. Fry,et al.  Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. , 1981, The Annals of thoracic surgery.

[31]  S. George,et al.  Planning the size and duration of a clinical trial studying the time to some critical event. , 1974, Journal of chronic diseases.

[32]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[33]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[34]  D.,et al.  Regression Models and Life-Tables , 2022 .